


PHARMACEUTICAL 2019

Adamas Pharmaceuticals Inc Rank 222 of 371





PHARMACEUTICAL 2019

Adamas Pharmaceuticals Inc Rank 222 of 371

The relative strengths and weaknesses of Adamas Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamas Pharmaceuticals Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Adamas Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is -228%, being 103% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	228,373
Cost of Goods Sold	633
Intangible Assets	0
Liabilities, Current	24,276
Liabilities, Non-Current	120,653
Other Assets	2,789
Other Compr. Net Income	-97
Other Expenses	15,977
Other Liabilities	0
Other Net Income	0
Property and Equipment	3,652
Research and Development	39,300
Revenues	34,046
Selling, General and Administrative Expense	109,135

Output Variable	Value in 1000 USD
Assets	234,814
Liabilities	144,929
Expenses	165,045
Stockholders Equity	89,885
Net Income	-130,999
Comprehensive Net Income	-131,048
Economic Capital Ratio	-228%